The t:slim X2 insulin pump is a small, tubed pump with a color touchscreen. Users can control the pump directly from the device or using an iPhone or Android smartphone app. The t:slim X2 is part of ...

This educational article was made possible with materials and support from Tandem Diabetes Care. Automated insulin delivery (AID) systems have been traditionally used by people with type 1 diabetes ...

A review of how far GLP-1 agonists have come – drugs for type 2 diabetes that help with not only blood sugar management, but with weight loss and heart health too GLP-1 agonists entered the type 2 ...

The American Diabetes Association recently released major diabetes care updates, which include new recommendations on diabetes technology, therapy, and preventative health. The ADA's annual Standards ...

Keeping blood sugars in balance is crucial for people with diabetes. Fenugreek, apple cider vinegar, and supplements like fiber and zinc are all-natural treatments that may help lower glucose levels.

On April 16, Medicare began covering people with type 2 diabetes for continuous glucose monitors (CGMs). In the largest expansion of continuous glucose monitoring coverage, Medicare expanded coverage ...

Zimislecel (VX-880) is an investigational islet cell therapy by Vertex that shows promise as a functional cure for type 1 diabetes. A study presented in June 2025 showed that, after one year, stem ...

Recent integrations between continuous glucose monitors and insulin pumps are allowing diabetes tech users to choose between more options. Tandem t:slim X2 users can now use either the FreeStyle Libre ...

Fully closed loop systems take automated insulin delivery a step further by skipping meal announcements. People with diabetes in the open source community are using fully closed loop systems, and ...

The FDA approved higher doses of the GLP-1 agonist, Trulicity, after powerful clinical trial results showed that the increased medication can help people lower their A1C and lose weight The FDA ...

The FDA has approved Novo Nordisk’s Awiqli (insulin icodec-abae), making it the first once-weekly basal insulin available in the U.S. for adults with type 2. This follows previous approvals from the ...

CagriSema is a once-weekly injection of semaglutide and cagrilintide. Clinical trial results for CagriSema showed significant improvements in A1C, weight loss, and time in range, marking it as a ...